New Therapeutic Area Study Assesses Market Forecast for Neurodegenerative Drugs Through 2013: Cutting Edge Information Report Analyzes Alzheimer's Disease, Multiple Sclerosis, and Parkinson's Disease Drug Portfolios and Market Prospects

RESEARCH TRIANGLE PARK, NC--(Marketwire - February 3, 2009) - Pharmaceutical business intelligence firm Cutting Edge Information today released a groundbreaking report that analyzes the fast-growing neurodegenerative disease landscape.

"Neurodegenerative Market Forecast to 2013" ( examines key trends currently affecting the neurodegenerative disease landscape and their impact on drug development and sales leading into the next decade. Although several diseases comprise the neurodegenerative field, the report focuses on Alzheimer's Disease, multiple sclerosis and Parkinson's Disease, the three illnesses that garner the most research and attention. The report details the historical, current and forecasted performance of 40 drugs -- marketed brands and pipeline products -- within these indications.

The report breaks data down by individual drug and by class. Besides providing in-depth discussions of each product, analysis compares data across brands and across classes -- leading to an honest and accurate evaluation of product/class performance: advantages, potential pitfalls, competitive threats, and clinical successes and failures. The study also gives insights on which pharma industry leaders are on track to dominate the markets' space.

"Patients with neurodegenerative diseases have few treatment options, and many of them are only marginally effective," said Jeremy Spivey, the report's lead author. "Companies that can make significant inroads with successful innovative treatments stand to earn billions in revenue. Our report gives them a strong foundation to understand the market and make decisions."

In developing this report, CEI analysts considered neurodegenerative drugs that are expected to earn more than $50 million in any one of the next five years. Drug classes within the report include:

Alzheimer's: acetylcholinesterase inhibitors, NMDA antagonists, and amyloid beta therapies

Multiple Sclerosis: interferon betas, immunomodulators, monoclonal antibodies

Parkinson's: dopaminergic drugs

The 201-page report ( consists of 40 brand profiles. These brand snapshots detail products' competitive and strategic positioning, market opportunities, and patent and litigation data. They include the following information:

--  Drug's current and projected competitive strength
--  Current/projected sales position within its class
--  Sales projection charts for the next four to seven years
--  Assessment of competition
--  Materiality charts
--  Clinical trial information

"Neurodegenerative Market Forecast to 2013" ( is the third Cutting Edge Information report providing market forecasts for therapeutic areas. Other reports focus on the oncology and diabetes markets.

Contact Information: CONTACT INFORMATION: Jeremy Spivey 919-433-0373